Moleculin Biotech, Inc. (MBRX) Stock Price
MBRXStock
$0.61−95.71%52W
Market Cap$11.90M
P/E—
PEG Ratio—
Div yield—
Beta1.98
MBRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-98.58%
Price vs S&P 500 (4W)-75.23%
VGM Score10.46
MBRX Earnings Surprise History
Q2 25-12.25est. -10.08
Q3 25-0.68est. -6.58
Q1 26-3.54est. -1.66
Q2 26-1.40est. -1.55
MBRX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MBRXMoleculin Biotech, Inc. | — | — | F | $0.61 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Moleculin Biotech, Inc.
Moleculin Biotech is a clinical-stage biopharmaceutical company developing a portfolio of drug candidates for resistant cancers and viral infections. The company's lead program, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance while reducing cardiotoxic side effects.